AS-Inclisiran sodium（Cat No.:I043629）is an investigational RNA-based therapy designed to treat hypercholesterolemia and cardiovascular diseases. It works by utilizing small interfering RNA (siRNA) to target and inhibit PCSK9, a protein that regulates low-density lipoprotein (LDL) cholesterol levels. By reducing PCSK9 expression, AS-Inclisiran sodium helps lower LDL cholesterol levels in the blood, thereby reducing the risk of cardiovascular events like heart attacks and strokes. Clinical trials are focused on assessing its safety, efficacy, and long-term benefits, with the potential to provide a novel, effective treatment option for patients with high cholesterol or atherosclerotic cardiovascular disease.